Neon Therapeutics ^{Priced, Nasdaq: NTGN}

We are a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Genetic mutations, which are a hallmark of cancer, can result in specific immune targets called neoantigens. The presence of neoantigens in cancer cells and their absence in normal cells makes them compelling, untapped targets for cancer therapy. We believe our neoantigen-targeted therapies will offer a new level of patient and tumor specificity in the field of cancer immunotherapy. NEO-PV-01, our personal neoantigen vaccine, is custom-designed and manufactured based on the unique mutational fingerprint of each individual patient. An initial trial demonstrated the ability of a personal neoantigen vaccine to generate highly specific immune responses in six patients with stage III/IV melanoma, and NEO-PV-01 is being evaluated in an ongoing Phase 1b trial in combination with nivolumab in metastatic melanoma, non-small cell lung cancer and bladder cancer. NEO-PTC-01, our personal neoantigen T cell therapy, consists of multiple T cell populations that are generated to target each individual patient's unique set of neoantigens.